

R&D COLLABORATIVE PROPOSAL / **COMPANY PARTNER SEARCH**

The information you are about to provide in this form will be distributed among Spanish companies matching your company profile and that might be interested in the proposal of collaborative R&D project that you will be describing in this form.
(Please use English language for filling in the document)

In the case that your company will establish a R&D project in collaboration with a Spanish company, your partner could benefit from the preferential financing given by CDTI under the frame of their International Cooperation Programs.



Company name: AnHorn Medicines Co., Ltd.

WEB site: www.anhornmed.com

Number of employees: 25-30

Year of Establishment: 2020

Activity/ sector: Biotech; new drug discovery; AI drug discovery

Key products and/or services: AH-001 clinical-stage drug discovery program for Androgenetic Alopecia and Acne;
AI drug discovery platform

Annual turnover: Balance Total: -

Address: 5F, No. 99, Ln. 130, Sec. 1, Academia Rd.,
Nangang Dist., Taipei 115, Taiwan (R.O.C.)

City: Taipei

Province: Taipei, Taiwan

Postal Code: 115

Telephone:

Fax:

Email:

Contact: Wendy Lin

Position: Business Development Director

Telephone: +886-2-2786-2568

Email: ywlin@anhornmed.com

Additional Contact:

Position:

Telephone:

Email:

YOUR COMPANY DESCRIPTION

(Activity description, main markets, strategic alliances, competitive position, share (%) of turnover due to exports, R&D resources and investment, partnerships with other companies or research organization, previous relationship with Taiwanese national R&D institutions, etc)

AnHorn Medicines is a biotechnology company founded in 2020 in Taipei, focused on transforming drug discovery through artificial intelligence and targeted protein degradation. By harnessing our proprietary AIMCADD® and BIGPRO® platforms, AnHorn has achieved remarkable speed and substantial cost savings in the development of new therapies, reducing timelines that traditionally take years into far shorter cycles. This efficiency enables the company to bring innovative treatments to patients faster while conserving resources for reinvestment into expanding its pipeline.

As part of its commitment to advancing AI-driven innovation, AnHorn is a member of the NVIDIA Inception Program, enabling access to advanced computing resources and technical collaboration to further enhance its drug discovery capabilities.

The company's lead candidate, AH-001, is being developed for androgenetic alopecia and acne, has already completed Phase I clinical trials in the United States, demonstrating strong safety and tolerability. The program showcases the breadth of AnHorn's therapeutic ambitions, spanning prescription aesthetics and cosmetic skin care.

Strategically, AnHorn is actively seeking global partnerships, with a primary focus on pipeline licensing and co-development opportunities targeting the European market. In parallel, the company is open to co-discovery collaborations with partners interested in leveraging its AI-driven platform to generate first-in-class or best-in-class drug candidates across multiple therapeutic areas.

With a growing patent portfolio, validated clinical assets, and a scalable AI infrastructure, AnHorn Medicines is well-positioned as a next-generation biotech partner—bridging cutting-edge technology with global drug development and commercialization opportunities.

COLLABORATIVE R&D PROJECT PROPOSAL

(Describe as precisely as possible the technology cooperation proposal and your main motivation, describe what you have to offer and what you expect from your potential Spanish partner from a technical point of view and from a commercial point of view, describe the profile of the Spanish company that you request, describe if you have previous contact with Spanish companies, additional comments)

AI-Driven Co-Discovery Collaboration

In parallel, AnHorn proposes a **strategic co-discovery partnership** to expand both parties' pipelines.

Collaboration Objectives

- Identify and develop novel targets using AI-driven approaches
- Generate small molecules or protein degraders for high-value indications
- Accelerate early-stage discovery with improved success probability

AnHorn Contribution

- Proprietary AIMCADD® (AI molecular design) platform
- BIGPRO® (protein degradation-focused discovery engine)
- Computational biology, chemistry, and AI expertise

Partner Contribution

- Disease biology expertise and target validation
- Translational and preclinical development capabilities
- Option to advance candidates into clinical development

Collaboration Model

- Joint steering committee for program selection and governance
- Shared IP or option-based licensing rights
- Milestone-based progression from discovery to clinical

Joint Clinical Development for AH-001 Program

AH-001 Program Overview

- **Indication:** Androgenetic Alopecia (AGA) and Acne
- **Modality:** Topical androgen receptor protein degrader (PROTAC)
- **Development Stage:** Completed Phase I clinical trials (U.S.)
- **Key Outcomes:**
 - Favorable safety and tolerability profile
 - Strong translational potential for efficacy studies

Value Proposition

- First-in-class / disease-modifying approach targeting androgen receptor degradation
- Topical delivery minimizes systemic exposure and improves patient compliance
- Significant market opportunity in both prescription therapeutics and aesthetic/cosmetic dermatology

Collaboration Objectives

- Advance AH-001 through Phase II/III clinical development in Europe for male-pattern hair loss
- Jointly develop the European clinical trial design and regulatory strategy
- Establish a clear path to commercial co-development and market access in Spain and select European territories
- Ensure mutual IP protection, transparent governance, and aligned incentives throughout the collaboration

AnHorn Contribution

- Co-investment in shared clinical development costs per agreed budget split
- Primary authorised IND filing in U.S. FDA
- Supply of GMP-grade clinical material for Phase I–II trials; technology transfer support for scale-up

Partner Contribution

- Lead EMA interactions; prepare and manage eCTD submissions in designated EU markets
- Contribute to clinical trial design and lead clinical operations in designated EU markets
- Co-investment in shared clinical development costs per agreed budget split
- Launch readiness planning for target territories

Collaboration Model

- Joint steering committee for program selection and governance
- Shared IP or option-based licensing rights
- Milestone-based progression from clinical to commercialization